New shot aims to tame hepatitis b in patients with low viral activity
NCT ID NCT07204236
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 25 times
Summary
This early-phase study tests a new injection called TVAX-008 in 20 adults with chronic hepatitis B who have very low virus levels or have lost the virus surface marker but not yet developed protective antibodies. The goal is to see if the injection can safely boost the body's immune response to better control the virus. Participants will be monitored for changes in antibody levels and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shandong Province Public Health Clinical Center
Jinan, Shandong, 250000, China
Conditions
Explore the condition pages connected to this study.